Stem cell grafts - Miltenyi Biotech

Drug Profile

Stem cell grafts - Miltenyi Biotech

Alternative Names: TCRabCD19PBSC

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Miltenyi Biotec GmbH
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cancer; Haematological disorders; Immunodeficiency disorders; Metabolic disorders

Most Recent Events

  • 09 Dec 2017 Interim efficacy, adverse events and immunogenicity data from a phase I/II in cancer, haematological disorders, immunodeficiency disorders and metabolic disorders presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
  • 03 Dec 2016 Adverse events data from a phase I/II trial in Cancer, Haematological disorders, Immunodeficiency disorders and Metabolic disorders presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top